Discovery Laboratories, Inc.

Discovery Laboratories, Inc.

Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania. Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The company's proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

Contact Details

Office Address

Discovery Laboratories, Inc.
1275 Peachtree St. NE
Atlanta, GA, USA 30309
Phone: (404) 892-3317
Fax: (404) 487-5705

Office Address

Discovery Laboratories, Inc.
2600 Kelly Road, Suite 100
Warrington, PA, USA 18976-3622
Phone: (215) 488-9300
Fax: (215) 488-9301

Executives

Chairman & Interim Chief Exec. Officer

Mr. W. Thomas Amick

Chief Financial Officer

Mr. John G. Cooper

Business Reviews for Discovery Laboratories, Inc.

Related Companies